Asfotase alfa

(Strensiq®)

Strensiq®

Drug updated on 11/10/2023

Dosage FormInjection (subcutaneous; 18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, 80 mg/0.8 mL)
Drug ClassTissue nonspecific alkaline phosphatase
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP)

Product Monograph / Prescribing Information

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Clinical practice guidelines for hypophosphatasia.2020Clinical Pediatric Endocrinology